ATX-10081-01 is a novel small molecule in preclinical development, functioning as a selective inhibitor of the androgen receptor. By blocking testosterone-driven tumor growth, this compound is under investigation… Read more
ATX-10081-01 is a novel small molecule in preclinical development, functioning as a selective inhibitor of the androgen receptor. By blocking testosterone-driven tumor growth, this compound is under investigation as a therapeutic candidate for advanced prostate cancer. Analytical laboratories supporting the research and characterization of this molecule require high-quality reference standards to ensure rigorous quality control. This category includes essential related compounds, such as impurities, metabolic degradation products, and stable isotope-labelled standards, which are critical for impurity profiling and the development of robust analytical methods. Utilizing these authenticated reference materials allows researchers to conduct accurate identification, quantification, and method validation throughout the preclinical stages of drug development.